An interventional study of The Ten Item Personality Inventory and Mechanistic Self-Dehumanization Condition in Mechanistic Self-Dehumanization Condition and Control Condition, sponsored by Florida State University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Florida State University · Not applicable, Interventional, and Basic science
PI (Morgan Robison) left to complete clinical internship
The goal of this experiment is to further determine if self-dehumanization is a novel risk factor for suicide. This study will induce self-dehumanization using a novel experimental self-dehumanized future condition (i.e., a futuristic paradigm that likens the individual to a machine) and compare this group to a control group to analyze the pathway between higher perceptions of self-dehumanization, suicidal ideation, and changes in oxytocin concentrations.
It is hypothesized that participants randomly assigned to the self-dehumanized mechanistic future condition will exhibit temporary increases in suicidal ideation (which will be thoroughly assessed, intervened upon following the induction) and decreases in oxytocin concentrations as compared to the control condition, which will not display significant changes. Further, we will explore if the magnitude of the oxytocin response will partially mediate the change in suicidal ideation.
Purpose: Humans are inherently social beings, and the need for belonging and connection is fundamental. Severe perceptions of social exclusion, non-belonging, and isolation can result in significant psychological harm, including suicide, which claims nearly 50,000 lives annually in the U.S. and affects over 13 million individuals through suicidal ideation (SI). A key predictor of SI, thwarted belongingness, arises from feelings of exclusion and non-belonging, yet more specificity is needed to identify the types of non-belonging that contribute most to suicide risk. Self-dehumanization-a perception of oneself as less than human-emerges as a promising factor in understanding and mitigating SI, with empirical evidence linking it to anxiety, depression, suicidal ideation, and social withdrawal. Preliminary research suggests that self-dehumanization is influenced by neurobiological processes, particularly oxytocin, a hormone critical to social connectedness and self-perception. Low oxytocin levels have been linked to self-dehumanization, reduced social reengagement, and heightened suicide risk, highlighting its potential as a target for intervention. Building on these insights, this study will experimentally induce and reduce self-dehumanization to examine its effects on SI and oxytocin levels. Thus, this study will use a self-dehumanization induction to analyze its impact on SI and oxytocin. Findings will provide a novel framework for integrating psychotherapeutic and neurobiological strategies into suicide prevention efforts.
Research Design/Method: The present study will utilize an experimental design with two groups, an experimental self-dehumanization induction group and a comparison control group.
Procedure: All interested participants will be instructed to fill out the screening survey to determine fit. Eligible participants will be invited to complete the study visit in person. Following consent, participants will complete a pre-induction fasted blood draw of 5 milliliters (i.e., approximately a tablespoon of blood). Next, participants will complete the Self-Injurious Thoughts and Behaviors-Short Form interview with the experimenter and a battery of randomized self-report assessments. After completion, participants will fill out a personality inventory distractor. Eligible participants will then be randomly assigned to one of two experimental conditions and provided a futuristic report based upon the false reports of the personality inventory. The two conditions will either be the mechanistic self-dehumanization condition or the control condition. Following this, they will undergo a post-induction 5 milliliter fasted blood draw. They will then complete a post-induction battery of self-report measures. Participants will be queried for any changes in suicide risk and any current suicidal ideation and intent will receive appropriate interventions (e.g., means safety counseling, safety planning). Upon completion participants will be debriefed, provided a brief rehumanization remedy to undo the effects of the self-dehumanized condition, compensated, and provided mental health resources (e.g., the National Suicide Prevention Lifeline). The appointment is expected to take approximately 1.5 hours to complete
Data Analyses: All results will be analyzed in R. First, descriptive statistics and zero-order bivariate correlation analyses will be assessed. For Study 1, repeated measures ANCOVAs will be used to examine group differences (i.e., the active self-dehumanization condition and control condition) in changes in oxytocin levels, self-dehumanization scores, and suicidal ideation, controlling for social isolation (i.e., thwarted belongingness, a factor of the Interpersonal Needs Questionnaire). Post-hoc pairwise comparisons will be conducted if the omnibus test indicates statistically significant effects. Following this, exploratory analyses will be conducted to assess if oxytocin partially mediates the relationship between self-dehumanization pre-experimental manipulation and suicide risk post-experimental manipulation (controlling for suicide risk at pre-experimental manipulation) through bootstrapped mediation procedures (i.e., 10,000 samples using the mediation and lavaan packages in R).
569 studies on the registry are indexed under Suicidal Ideation; 203 are open to participants now.
Browse Suicidal Ideation studies →Florida State University is the lead sponsor of 249 studies on the registry; 47 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A self-dehumanized future condition (i.e., a futuristic paradigm that likens the individual to a machine)
Other: The Ten Item Personality Inventory · Other: Mechanistic Self-Dehumanization Condition · Other: Debrief · Diagnostic Test: Clinical Interview · Other: Self-Report Measures · Other: Blood Draw
Control Condition
Other: The Ten Item Personality Inventory · Other: Control Condition · Diagnostic Test: Clinical Interview · Other: Self-Report Measures · Other: Blood Draw
The Ten Item Personality Inventory (TIPI) is a brief self-report measure of the Big Five personality dimensions, which will provide the mock basis for the self-dehumanization induction. Participants will indicate responses on 7-point Likert scale ranging from 1 ("disagree strongly") to 7 ("agree strongly"). Building off previously validated tasks participants will be told that the TIPI measure provided certain information about their personalities (and therefore expectations for their future). To establish credibility, participants will receive accurate feedback surrounding their reported levels of extraversion (high, medium, low). Participants will be randomly assigned to receive one of the following pre-written, feedback scripts as additional implications about their extraversion scores in relationship to future social expectations.
Future Mechanistic Self-Dehumanization Script: "Based on your responses, you're the type who will feel at times that you're just a number in the system. The day-to-day pattern of going to work and fulfilling responsibilities will seem repetitive, like you are a mechanical device just going through the motions. You might find that relationships feel distant or lack the warmth you seek, making it challenging to form deeper connections. Over time, each day will blend into the next, which will likely lead to you operating on autopilot, existing among humans."
Debrief: Those in the self-dehumanized condition will receive a brief rehumanization intervention to undo the effects of the self-dehumanized condition. This intervention will involve a reminder that the condition was fabricated and will involve reading quotes involving general themes of humanness. The participants will then share with the experimenter how they connect to their humanness. The experimenter will document responses and encourage engagement in humanizing activities following the study visit. Findings from these qualitative responses will inform a rehumanization intervention in another study.
Future Control Script: "Based on your responses, you're the type who will have a very normal life. You will wake up, go to your job during the weekdays, and complete all necessary tasks. On the weekends you will spend time doing fulfilling activities. Relationships will have natural ups and down, but overall, you will feel satisfied by your connectedness to others. Though some days may feel monotonous, you will feel relaxed knowing you belong."
Clinical Interview. Self-Injurious Thoughts and Behaviors Interview-Short Form (SITBI-SF). Participants will complete an in-person interview featuring 72-items about their history of self-injury and suicidal behaviors. This interview includes 6 yes/no style questions about suicidal thoughts, suicidal plans, suicidal gestures, suicidal attempts, nonsuicidal self-injury thoughts, and nonsuicidal self-injury. Each category that is endorsed, across the lifetime, has follow up questions surrounding times, duration, intensity, severity, type, and if medical attention was sought. This interview has sound psychometric properties.
Depressive Symptom Index - Suicidality Subscale (DSI-SS). Patient Health Questionnaire-8 (PHQ-8). Interpersonal Needs Questionnaire (INQ). Self-Dehumanization Scale (SDS).
Five milliliters of blood will be drawn before and after study interventions for the quantification of plasma oxytocin concentrations by certified phlebotomists. Samples will be collected into chilled Ethylenediaminetetraacetic Acid (EDTA) tubes, inverted ten times to mix with anticoagulants, and centrifuged at 1600g for 15 minutes at 4˚C. Cleared plasma will be aliquoted into cryotubes and stored at -80˚C. Consistent with expert recommendations, oxytocin levels will be obtained from the samples diluted 1:4 (i.e., oxytocin can be discarded through plasma proteins when incorporating an extraction step before conducting the enzyme-linked immunosorbent assay \[ELISA\]). Second, to buffer against contrasting concerns, an aliquot of each sample will be analyzed for test-retest purposes. Oxytocin concentrations will be measured using a validated commercially available and sensitive ELISA neurophysin kit (Abcam).
Change in Suicidal Ideation
Suicidal Ideation will be measured using the Depressive Symptom Index-Suicidality Subscale (DSI-SS) where the scores range from 0-12 and higher scores indicate higher levels of suicidal ideation. These analyses will control for Baseline suicidal ideation and the thwarted belongingness sub-scale from the Interpersonal Needs Questionnaire where thwarted belongingness scores range from 1-56 and higher scores indicate greater perceptions of thwarted belongingness.
Time frame: Baseline and 1 hour later after the experimental induction
Change in Oxytocin Levels
Five milliliters of blood will be drawn before and after study interventions for the quantification of plasma oxytocin concentrations by certified phlebotomists (including the PI, who is already certified and currently collecting samples for a T-32 supported project). Samples will be collected into chilled EDTA tubes, inverted ten times to mix with anticoagulants, and centrifuged at 1600g for 15 minutes at 4˚C. Cleared plasma will be aliquoted into cryotubes and stored at -80˚C. Consistent with expert recommendations, oxytocin levels will be obtained from the samples diluted 1:4 (i.e., oxytocin can be discarded through plasma proteins when incorporating an extraction step before conducting the enzyme-linked immunosorbent assay \[ELISA\]). Second, to buffer against contrasting concerns, an aliquot of each sample will be analyzed for test-retest purposes. Oxytocin concentrations will be measured using a validated commercially available and sensitive ELISA neurophysin kit (Abcam).
Time frame: Baseline and 1 hour later after the experimental induction
Plan to share: Undecided — Protocol will be designed to allow for IPD sharing. IPD de-identified demographic, self-report, and neurobiological (i.e., oxytocin) data may be shared. Data will not be shared if the participant denies to share their data. Data will be accessible by contacting the Central Contact Person of the study: Morgan Robison (mrobison@psy.fsu.edu). If data are uploaded to a public repository, the external link will be made available here.
PI (Morgan Robison) left to complete clinical internship
PI (Morgan Robison) left to complete clinical internship
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.